News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

OKINADA: TNF inhibition disappoints in knee osteoarthritis
10 Jun 2022
byJairia Dela Cruz
Short-term tumour necrosis factor (TNF) inhibition with adalimumab falls short of producing improvements in patients with radiographic knee osteoarthritis, according to the proof-of-concept OKINADA trial presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.
10 Jun 2022

Obefazimod 50 mg for rheumatoid arthritis delivers in phase II trial
10 Jun 2022
The investigational drug ABX464, also known as obefazimod, helps reduce disease activity in patients with rheumatoid arthritis (RA), according to the results of a phase II trial. The 50-mg dose is well tolerated, while the higher dose is associated with mild-to-moderate adverse effects resulting in treatment discontinuation.
10 Jun 2022







